University Repurposing Trials Deliver Generic Drugs at 90% Lower Cost

The Cambridge Law Journal study documents how academic centers bypass pharmaceutical R&D economics by selecting already-approved generics whose safety profiles are established. Trial expenses drop because investigators draw on existing manufacturing, institutional review boards, and grant funding rather than venture capital. Examples include an anti-VEGF oncology agent tested for macular degeneration, tamoxifen repositioned for prevention, and colchicine evaluated for COVID-19 inflammation. These efforts operate outside patent incentives yet produce usable evidence for clinical practice.

Lower barriers arise from reduced financial risk and different motivations: career advancement through publication and direct patient benefit rather than market exclusivity. Expertise thresholds fall because prior toxicology and dosing data already exist. Governments in Europe and Australia have begun formal recognition programs that reimburse such trials, signaling policy uptake of this parallel system.

Industry continues to file roughly 32 supplemental indications yearly while generics are still protected, but interest collapses post-exclusivity. Academic repurposing fills that gap at scale. Remaining questions include whether payers will routinely cover off-label use supported only by non-industry data and how regulators will weight academic versus sponsor-submitted dossiers.

Next steps require prospective registries tracking approval rates and real-world adoption of academically generated indications. Comparative cost-effectiveness studies against de novo molecules would quantify the claimed savings.